Key result
In Brazil, the prevalence of hypertension and dyslipidemia were 23% and 40.8%, respectively, with significant gaps in hypertension awareness (22.2%) and dyslipidemia treatment (30.0%).
Why the study?
Systemic arterial hypertension and dyslipidemia are poorly studied in terms of patient journey aspects.
Systematic Review
There are significant gaps in patient awareness and treatment of dyslipidemia and hypertension in Brazil, highlighting the need for improved patient education and healthcare resource allocation.
Answers are grounded in this paper and cite their sources.
Highlights barriers to SAH/dyslipidemia care in Brazil; supports tailored patient-journey interventions pending prospective trials.
BACKGROUND AND OBJECTIVE: Non-communicable diseases like systemic arterial hypertension (SAH) and dyslipidemia are poorly studied in terms of patient journey aspects. This semi-systematic review provides evidence synthesis for the management of SAH and dyslipidemia in Brazil and also discusses challenges faced by patients at the local level along with a suggested care approach by local experts. METHODS: A semi-systematic review using both structured literature databases (Embase and Medline) and unstructured scientific records (WHO, IPD, MOH and Google) on hypertension and dyslipidemia in the English language from 2010 to 2019 was performed by reviewers. After two-level screening based on pre-defined criteria, patient journey touchpoints and prevalence information were extracted from the included articles. Data gaps were bridged through the insights of local experts. RESULTS: Prevalence of hypertension and dyslipidemia in Brazil were 23% and 40.8%, respectively. Awareness of dyslipidemia was found in a larger proportion (58.1%) than in SAH (22.2%). Similarly, screening for hypertension (97%) and dyslipidemia (55.4%) were found to be effective, while treatment was (62.9%) and (30.0%) for hypertension and dyslipidemia, respectively. CONCLUSION: There were important gaps on patient awareness and treatment of dyslipidemia and hypertension. Limited patient education, regional disease distribution, and treatment allocation, along with limited resources for diagnosis and treatment are the key challenges.
No takes yet. Share an insight, caveat, or question.
Faria‐Neto et al. (2022) conducted a systematic review in Systemic arterial hypertension and dyslipidemia. Systemic arterial hypertension and dyslipidemia was evaluated on Prevalence, awareness, screening, and treatment rates. In Brazil, the prevalence of hypertension and dyslipidemia were 23% and 40.8%, respectively, with significant gaps in hypertension awareness (22.2%) and dyslipidemia treatment (30.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: